(2S,3R)-3-hydroxy-2-(3-((S)-1-(3-(pyrazin-2-yl)-1,2,4-oxadiazol-5-yl)but-3-ynyl)ureido)butanoic acid

ID: ALA4461906

Chembl Id: CHEMBL4461906

PubChem CID: 155528773

Max Phase: Preclinical

Molecular Formula: C15H16N6O5

Molecular Weight: 360.33

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  C#CC[C@H](NC(=O)N[C@H](C(=O)O)[C@@H](C)O)c1nc(-c2cnccn2)no1

Standard InChI:  InChI=1S/C15H16N6O5/c1-3-4-9(18-15(25)19-11(8(2)22)14(23)24)13-20-12(21-26-13)10-7-16-5-6-17-10/h1,5-9,11,22H,4H2,2H3,(H,23,24)(H2,18,19,25)/t8-,9+,11+/m1/s1

Standard InChI Key:  DGLNBPSKIUYJIJ-YWVKMMECSA-N

Alternative Forms

1. Parent:

   

   ALA4461906

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 360.33

Molecular Weight (Monoisotopic): 360.1182

AlogP: -0.28

#Rotatable Bonds: 7

Polar Surface Area: 163.36

Molecular Species: ACID

HBA: 8

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 11

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.94

CX Basic pKa: 0.39

CX LogP: -0.68

CX LogD: -3.90

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.49

Np Likeness Score: -1.35

References

1. Blevins DJ, Hanley R, Bolduc T, Powell DA, Gignac M, Walker K, Carr MD, Hof F, Wulff JE..  (2019)  In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action.,  10  (8): [PMID:31413804] [10.1021/acsmedchemlett.9b00221]

2. Chen T, Li Q, Liu Z, Chen Y, Feng F, Sun H..  (2019)  Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?,  161  [PMID:30384043] [10.1016/j.ejmech.2018.10.044]

Source

Source(1):

• Scientific Literature